PMID- 21740296
OWN - NLM
STAT- MEDLINE
DCOM- 20120713
LR  - 20190116
IS  - 1029-2403 (Electronic)
IS  - 1026-8022 (Linking)
VI  - 52
IP  - 12
DP  - 2011 Dec
TI  - Morphological, immunophenotypic and molecular characterization of mature 
      aggressive B-cell lymphomas in Chinese pediatric patients.
PG  - 2356-64
LID - 10.3109/10428194.2011.602772 [doi]
AB  - Differential diagnosis of Burkitt lymphoma (BL), diffuse large B-cell lymphoma 
      (DLBCL) and B cell lymphoma, unclassifiable, with features intermediate between 
      BL and DLBCL (intermediate BL/DLBCL) can be difficult. We studied 97 Chinese 
      pediatric mature aggressive B-cell lymphomas including 81 BL cases, eight DLBCL 
      cases and eight intermediate BL/DLBCL cases using immunohistochemistry, 
      interphase fluorescence in situ hybridization (FISH) and Epstein-Barr virus (EBV) 
      in situ hybridization. Our results showed that there were no significant 
      differences in the expression of CD10 and BCL6 among cases of BL (91% and 86%, 
      respectively), DLBCL (75% and 63%, respectively) and intermediate BL/DLBCL (75% 
      and 63%, respectively) (p > 0.05). The expression of BCL2 (3% in BL, 50% in 
      DLBCL, 50% in intermediate BL/DLBCL), expression of MUM1 (17% in BL, 63% in 
      DLBCL, 63% in intermediate BL/DLBCL) and mean Ki-67 proliferation index (PI) (93% 
      in BL, 83% in DLBCL, 80% in intermediate BL/DLBCL) were significantly different 
      between BL and DLBCL and between BL and intermediate BL/DLBCL. The frequency of 
      an extra copy of BCL6 (0% in BL, 37.5% in DLBCL, 25% in intermediate BL/DLBCL) 
      and EBV-encoded RNA (EBER) positivity (48% in BL, 0% in DLBCL and intermediate 
      BL/DLBCL) were also significantly different between BL and DLBCL and between BL 
      and intermediate BL/DLBCL. The frequency of C-MYC rearrangement in BL (98%) was 
      much higher than in DLBCL (37.5%) and intermediate BL/DLBCL (50%). Our findings 
      suggest that diagnosis of the mature aggressive B-cell lymphomas in pediatrics 
      should be based on the comprehensive review and integration of morphological, 
      immunohistochemical and molecular genetic features. The expression of CD10 and 
      BCL6 but not BCL2, a high Ki-67 PI (>90%) and a C-MYC rearrangement but not BCL2 
      or BCL6 rearrangement are the features of BL. MUM1 is not an exclusionary 
      diagnostic marker for BL. As the immunophenotype and molecular genetic features 
      of DLBCL and intermediate BL/DLBCL are similar, intermediate BL/DLBCL is more 
      likely a subgroup of DLBCL in the pediatric population. Regardless of the 
      expression of CD10 and BCL6, strong staining for BCL2, Ki-67 PI below 90% and the 
      presence of extra copies of BCL6 favor a diagnosis of DLBCL or intermediate 
      BL/DLBCL.
FAU - Lu, Beibei
AU  - Lu B
AD  - Department of Pathology, Basic Medical College, Capital Medical University, 
      Beijing, China.
FAU - Zhou, Chunju
AU  - Zhou C
FAU - Yang, Wenping
AU  - Yang W
FAU - Huang, Hui
AU  - Huang H
FAU - Gao, Zifen
AU  - Gao Z
FAU - He, Yaoxin
AU  - He Y
FAU - Liu, Hongxiang
AU  - Liu H
FAU - Zhou, Xiaoge
AU  - Zhou X
FAU - Gong, Liping
AU  - Gong L
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110818
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
RN  - 0 (Biomarkers, Tumor)
SB  - IM
MH  - Adolescent
MH  - Biomarkers, Tumor/genetics/metabolism
MH  - Child
MH  - Child, Preschool
MH  - China
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - Immunophenotyping
MH  - In Situ Hybridization, Fluorescence
MH  - Infant
MH  - Lymphoma, B-Cell/*diagnosis/genetics/pathology
MH  - Male
EDAT- 2011/07/12 06:00
MHDA- 2012/07/14 06:00
CRDT- 2011/07/12 06:00
PHST- 2011/07/12 06:00 [entrez]
PHST- 2011/07/12 06:00 [pubmed]
PHST- 2012/07/14 06:00 [medline]
AID - 10.3109/10428194.2011.602772 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2011 Dec;52(12):2356-64. doi: 10.3109/10428194.2011.602772. Epub 
      2011 Aug 18.